Skip to content

A Trial of Topical Aloe Vera Gel in Emergency Department Patients Presenting With Simple Traumatic Wounds

A Parallel Group Double Blind Placebo Randomised Controlled Trial (RCT) of Topical Aloe Vera Gel in Emergency Department (ED) Patients Presenting With Simple Traumatic Wounds

Status
Withdrawn
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02819817
Acronym
ALOE
Enrollment
0
Registered
2016-06-30
Start date
2017-04-30
Completion date
2019-02-28
Last updated
2017-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Injuries and Wounds

Keywords

Aloe Vera, wound, healing

Brief summary

This is a double blind placebo-controlled RCT comparing the speed of healing of simple traumatic wounds with Aloe Vera gel compared to both control (Ultrasound gel) and standard care.

Detailed description

Simple traumatic wounds are a common presenting symptom to the ED affecting thousands of patients worldwide every day. Aloe Vera is a natural product that has been linked to better healing both anecdotally and in animal studies. A recent Cochrane review failed to find any human studies on acute wounds such as those seen in the ED. The aim of this study is to see whether Aloe Vera gel improves the wound healing time in these patients. We plan to enrol 270 participants presenting to the Royal Infirmary of Edinburgh ED with simple traumatic wounds into a randomised controlled trial. Participants will be assessed at baseline using the Bates-Jensen wound assessment tool. They will be then be randomized to one of three groups, and allocated to receive either Aloe Vera gel, control (Ultrasound gel) or standard care. The participants in the two gel groups will have identical packaging and the treating clinician will be unaware as to which group they are allocated. They will be asked to place the allocated substance onto the wound twice daily and cover with a supplied dressing on each occasion for 1 week. All groups will be asked to return to the ED for a repeat Bates-Jensen wound assessment, and will also be asked to record the number of days that their wound took to heal. The gel groups will have assessment of product usage. Participants will also be telephoned at 3 weeks. Primary outcome will be number of days for wound to heal. Secondary outcome will be change in Bates-Jensen wound assessment score between baseline and day 10, change in wound size between baseline and day 10 and baseline and day 21, changes in wound characteristics at day 21 as reported by participants, wound infection rate, participant satisfaction and participant compliance with treatment.

Interventions

The participant will be asked to place the allocated substance onto the wound twice daily and cover with a supplied dressing on each occasion for 1 week.

The participant will be asked to place the allocated substance onto the wound twice daily and cover with a supplied dressing on each occasion for 1 week.

Sponsors

University of Edinburgh
CollaboratorOTHER
NHS Lothian
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients deemed by their treating clinician to have a simple traumatic wound will be considered for enrolment.

Exclusion criteria

1. Known allergy to either Aloe Vera or ultrasound gel 2. Patients under 16 year of age 3. No telephone number for follow-up 4. Patient lacking capacity 5. Patient currently using antibiotics 6. Patient having a puncture or bite wound 7. Patient having underlying tendon or bone involvement or wound overlying a joint 8. Patients with burn wounds 9. Wounds more than 24 hours old 10. Patient unable/unwilling to attend follow-up 11. Patients unable to self administer treatment. 12. Wound that treating clinician would not routinely dress e.g. facial wounds (face, ear, eyebrow, nose, lip, eyelid, scalp), mucosa and hair covered areas, or wounds that require specialist dressing 13. Self reported pregnancy 14. Patients with a known allergy to the study dressing 15. Patients currently recruited in another clinical trial 16. Patients already recruited in the ALOE Study

Design outcomes

Primary

MeasureTime frame
Number of days for wound to heal (defined as epithelial closure without discharge or scab formation)Day 21 (+/- 2 days)

Secondary

MeasureTime frame
Size (width and height in mm) of wound at baseline, day 10 (+/- 2 days), and day 21 (+/- 2 days)Baseline, day 10 (+/- 2 days) and day 21 (+/- 2 days)
Characteristics (visibility of wound edges and leakage from wound) as reported by participant at day 21 (+/- 2 days)Day 21 (+/- 2 days)
Numerical change in Bates-Jensen wound assessment score between baseline and day 10 (+/- 2 days)Baseline and day 10 (+/- 2 days)
Participant satisfaction scoreDay 21 (+/- 2 days)
Participant treatment compliance (i.e. the total weight of gel used)Day 10 (+/- 2 days)
Wound infection rateDay 21 (+/- 2 days)

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026